Adagio Medical Holdings, Inc Common Stock (ADGM)vsBoston Scientific Corp (BSX)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.62
-3.32%
HEALTHCARE · Cap: $16.55M
BSX
Boston Scientific Corp
$44.20
-0.58%
HEALTHCARE · Cap: $69.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 15046616% more annual revenue ($20.61B vs $137,000). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).
ADGM
Avoid35
out of 100
Grade: F
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADGM.
Margin of Safety
-18.7%
Fair Value
$37.36
Current Price
$44.20
$6.84 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Reasonable price relative to book value
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while BSX is a mature play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.56 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 35/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing cardiac arrhythmia treatment through its state-of-the-art medical technologies. Utilizing its proprietary platform, the company is at the forefront of developing advanced targeted ablation techniques, addressing unmet needs in the electrophysiology sector. With a robust product pipeline and a seasoned leadership team, Adagio represents a compelling investment opportunity for institutional investors looking to capitalize on growth in the healthcare industry and contribute to improvements in cardiac patient outcomes.
Visit Website →Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?